beyond glp-1 GLP-1: Review of Next-Generation Obesity Therapeutics BEYOND OZEMPIC PROMO

doi: 10.2337/dc20-S009 6 ArpaiaN.CampbellC.FanX.DikiyS.van der VeekenJ.deRoosP.et al

Instead, the test may help contextualize which compounded option (semaglutide, tirzepatide, or microdose protocol) warrants first-line consideration based on your genetic profile

Eating smarter matters more than eating more

According to the study, GLP-1 medicines reduced body fat in obese mice much more than lean body mass, and fat and liver mass fell faster than skeletal muscle

Nausea Diarrhea Vomiting Constipation It should be understood that there is no long-term data, as even Ozempic has only been on the market for about 8 years